Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

€35.6 Million in Cash and Cash Equivalents as of March 31, 2018

20180426-Resultats-Q1-2018-EN

Published 26 April 2018
Categorized as 2018, Press release

Pseudocowpox: A next generation viral vector for cancer immunotherapy

Karolina Rittner, et al. AACR 2018, April 2018 – Abstract available on the AACR 2018 website Download the poster here Poster Presentation

Published 18 April 2018
Categorized as -others, 2018, Publication

Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018

20180418 AACR 2018 poster PCPV – EN

Published 18 April 2018
Categorized as 2018, Press release

TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma

Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 Download the poster here Poster Presentation

Published 17 April 2018
Categorized as -others, 2018, Publication, TG6002

Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses

20180321-Resultats-2017-EN

Published 21 March 2018
Categorized as 2018, Press release

Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018

20180315 PR AACR LB poster accepted

Published 15 March 2018
Categorized as 2018, Press release

First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)

20180117 PR FPI T101

Published 17 January 2018
Categorized as 2018, Press release, TG1050

First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)

20180116 PR FPI TG4010 1L EN

Published 16 January 2018
Categorized as 2018, Press release, TG4010

Transgene Announces Financial Calendar for 2018

20171221 Financial calendar 2018 EN

Published 21 December 2017
Categorized as 2017, Press release

Transgene Announces Upcoming Investor Meetings

20171218 PR financial agenda T1 18

Published 18 December 2017
Categorized as 2017, Press release

Posts pagination

Newer posts Page 1 … Page 34 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu